10 September 2018
An innovative chemical composition of naturally occurring compounds in the human body is about to hit the mass market in the form of a functional beverage. This could be a major breakthrough in the on-going battle to maintain mental and cognitive health of the ageing population of our planet for longer. The name we have given to this novel composition, being developed as an essential everyday dietary ingredient to sustain high energy reserves in the human brain, is Mitocholine. MSI Ltd, a London-based company researching and developing the composition of Mitocholine, has received Innovate UK support to take Mitocholine through global Novel Food approval and also clinical trials that will establish the validity of our claims.
For anyone with knowledge of brain chemistry the simplicity of the formula speaks for itself. The simplicity of the delivery method, as a functional drink, also means it will be affordable and available to the general public.
This scientific development, and its planned consumption on a regular basis, has been compared by some specialists to the discovery of the beneficial properties of water fluoridation in tooth decay reduction.
The science behind this breakthrough: Mitocholine’s components, when taken orally, become available to the brain and can potentially delay the process of ageing by sustaining energy reserves and by increasing insulin receptor sensitisation in the brain cells. Mitocholine delivers essential substrates to the energy generating intracellular machinery (mitochondria) simultaneously with the support of insulin action in the brain.
“Mitocholine will keep the human brain healthy for longer. Mitocholine is suitable for everyday consumption and long-term use by the general population – the product is effective at any age with both short term and long-term beneficial effects”, says Dr Larisa Andreeva, the Founder and Managing Director of MSI Ltd. “Our ambition is to deliver Mitocholine as an everyday standard of human preventive care for keeping the brain healthy and delaying or preventing the onset of dementia”.
How it works
Mitocholine is a patent protected chemical composition of three essential human metabolites capable of reaching the brain and working in synergy to fill, enhance and maintain energy reserves in the brain. The three components in our innovative composition of Mitocholine are: choline, succinate and nicotinamide which, when taken orally, become available to the brain cells. One part of Mitocholine’s composition comes in a form of salt and was synthesised by one of MSI’s founders who has 30 years of chemical experience in succinic salts. Demanding conditions of modern everyday life are draining the brain of energy reserves, thus making people vulnerable and susceptible to stress and mental fatigue, which in turn leads to loss of productivity and social problems. Brain energy generation metabolism starts to decline on average from the age of 45. We believe Mitocholine will sustain the level of energy reserves in the human brain and help to prevent cognitive decline in stressful situations and in old age. The proprietary protection for Mitocholine’s composition lists prevention and dietary management of symptoms and physiological conditions associated with imbalanced, or age-related slowed brain energy metabolism in a human subject. This approach is substantiated by numerous research articles published over the last decade, an informal clinical trial and 31P MRI measurements of energy reserves in the human brain.
The Innovate UK funding, allocated for a 3-year commercialisation programme, has transformed MSI Ltd into a product prototype stage company. Our aim is to achieve global marketing authorisation for Mitocholine as a Novel Food. It is rather fortuitous that, rather than having to pursue approval for Mitocholine through the pharmaceutical route in a process that can take over a decade, we are able to seek Novel Food approval. We expect this process to be rapid as all components of the final composition are known human metabolites which are inventively formulated. Mitocholine’s compounds are used individually for human consumption and already have previously established Adequate Intake (AI) levels. According to US consumption data from 2007-2010, 92% of the US population failed to consume the AI for choline.
MSI Ltd is ready to start out-licensing the composition in order to facilitate fast market delivery. In parallel MSI will substantiate Mitocholine’s impact as an everyday diet ingredient through a series of clinical trials and also establish Mitocholine as a clinically validated product for the improvement of human health span and as an essential anti-aging ingredient for the active brain.